Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Cristina Knape"'
Autor:
Uri Greenbaum, Kimberly Klein, Fernando Martinez, Juhee Song, Peter F. Thall, Jeremy L. Ramdial, Cristina Knape, Fleur M. Aung, Jamie Scroggins, Adriana Knopfelmacher, Victor Mulanovich, Jovan Borjan, Javier Adachi, Mayoora Muthu, Cerena Leung, Mayrin Correa Medina, Richard Champlin, Amanda Olson, Amin Alousi, Katayoun Rezvani, Elizabeth J. Shpall
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundCOVID-19 Convalescent plasma (CCP) is safe and effective, particularly if given at an early stage of the disease. Our study aimed to identify an association between survival and specific antibodies found in CCP.Patients and MethodsPatients
Externí odkaz:
https://doaj.org/article/e8c03ca534d6409a85e0928d9fbecfca
Autor:
Maro Ohanian, Farhad Ravandi, Maria E Suarez-Almazor, Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Stephen Gruschkus, May Daher, Richard Champlin, Kaysia Ludford, Guillermo Garcia-Manero, Hind Rafei, Jacinth Joseph, Gabriela Rondon, Laura Whited, Faisal Fa'ak, Cristina Knape, Mahran Shoukier, Megan Marcotulli, Alison M Gulbis, Betul Oran, Uday R Popat, Rotesh Mehta, Amin M Alousi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-
Externí odkaz:
https://doaj.org/article/10e93fbbcd6b4e969d6a3f82162fa2d6
Autor:
Jitesh D. Kawedia, Xiaoqian Liu, Jeremy Ramdial, Samer A. Srour, Rohtesh S. Mehta, Uday R. Popat, Yago Nieto, Neeraj Y. Saini, Partow Kebriaei, Cristina Knape, Alison M. Gulbis, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Qaiser Bashir
Publikováno v:
Transplantation and Cellular Therapy. 29:S438-S439
Autor:
Jitesh D Kawedia, Xiaoqian Liu, Jeremy Ramdial, Samer A Srour, Rohtesh S. Mehta, Uday R Popat, Yago Nieto, Neeraj Y Saini, Partow Kebriaei, Cristina Knape, Alison M. Gulbis, Richard E Champlin, Elizabeth J Shpall, Muzaffar H. Qazilbash, Qaiser Bashir
Publikováno v:
Transplantation and Cellular Therapy. 28:S461-S462
Autor:
Jeremy Ramdial, Cerena Leung, Mayrin Correa Medina, Amanda Olson, Kimberly Klein, Jamie Scroggins, Jovan Borjan, Javier A. Adachi, Victor E. Mulanovich, Richard E. Champlin, Cristina Knape, Amin M. Alousi, Elizabeth J. Shpall, Juhee Song, Katayoun Rezvani, Peter F. Thall, Mayoora Muthu, Fernando J. Martinez, Uri Greenbaum, Adriana Knopfelmacher, Fleur M. Aung
Publikováno v:
medRxiv
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
BackgroundCOVID-19 Convalescent plasma (CCP) is safe and effective, particularly if given at an early stage of the disease. Our study aimed to identify an association between survival and specific antibodies found in CCP.Patients and MethodsPatients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad4805c060623750777ee90e6b7c5556
https://doi.org/10.1101/2021.03.08.21252775
https://doi.org/10.1101/2021.03.08.21252775
Autor:
Jitesh D. Kawedia, Muzaffar H. Qazilbash, Cristina Knape, Dawen Sui, Qaiser Bashir, Peter F. Thall
Publikováno v:
Blood. 136:37-38
Background: High-dose chemotherapy followed by autologous hematopoietic cell transplantation (auto HCT) is considered to be the standard of care treatment for transplant-eligible patients with multiple myeloma (MM). The most commonly used conditionin
Autor:
Laura K. Whited, Jacinth Joseph, Gheath Alatrash, Megan Cornelison-Marcotulli, Rohtesh S. Mehta, Marina Konopleva, Gabriela Rondon, Ala Abudayyeh, Chantal Saberian, Guillermo Garcia-Manero, Naval Daver, Amin M. Alousi, Hind Rafei, Uday R. Popat, Cristina Knape, Richard E. Champlin, Noha Abdel-Wahab, May Daher, Maro Ohanian, Adi Diab, Farhad Ravandi, Stephen K. Gruschkus, Betul Oran, Alison M. Gulbis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S201-S202
Context There are concerns that the use of immune checkpoint inhibitors (ICIs) after allogeneic stem cell transplant (allo-SCT) may increase the incidence of acute graft-versus-host disease (aGVHD). Objective We report our experience with ICIs used a
Autor:
Gheath Alatrash, Farhad Ravandi, Rohtesh S. Mehta, Stephen K. Gruschkus, Betul Oran, May Daher, Cristina Knape, Chantal Saberian, Ala Abudayyeh, Guillermo Garcia-Manero, Richard E. Champlin, Amin M. Alousi, Megan Marcotulli, Noha Abdel-Wahab, Laura K. Whited, Jacinth Joseph, Gabriela Rondon, Hind Rafei, Alison M. Gulbis, Maro Ohanian, Adi Diab, Uday R. Popat, Marina Konopleva, Naval Daver
Publikováno v:
Blood. 136:1-1
Background: Allogeneic hematopoietic stem cell transplantation (alloHCT) remains a curative approach for patients with AML/MDS. Still, up to 50 % of patients relapse after alloHCT. Immune checkpoint inhibitors (ICI) are being used in the post-transpl